Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
1(33.3%)
Phase 1
1(33.3%)
N/A
1(33.3%)
3Total
Early Phase 1(1)
Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05860595Not ApplicableActive Not Recruiting

Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.

Role: collaborator

NCT05882487Early Phase 1Not Yet Recruiting

Safety and Efficacy Study of KL002 in the Treatment of Advanced Primary PD

Role: collaborator

NCT03517631Phase 1Unknown

An Efficacy and Safety Study of shRNA-modified CD34+ Cells in HIV-infected Patients.

Role: collaborator

All 3 trials loaded